论文部分内容阅读
目的探讨普米克令舒联合氨溴索雾化在治疗晚期新生儿肺炎患儿中的应用价值。方法将晚期新生儿肺炎患儿随机分为实验组和对照组,对照组给予积极抗感染和对症治疗,实验组除外对照组处理还给予普米克令舒联合氨溴索雾化吸入治疗,比较两组患儿疗效、症状体征改善情况。结果实验组疗效整体优于对照组,且在退热时间、体征变化时间和住院时间上早于对照组,差异有统计学意义(P<0.05)。结论普米克令舒联合氨溴索雾化治疗晚期新生儿肺炎效果显著,能明显提高患儿治愈率,改善患儿临床症状和体征并缩短病程。
Objective To investigate the value of pulmicort respules combined with ambroxol in the treatment of neonates with neonatal pneumonia. Methods The children with advanced neonatal pneumonia were randomly divided into experimental group and control group. The control group was given positive anti-infective and symptomatic treatment. The control group was treated with pulmicort resp. Ambroxol inhalation. Group children efficacy, improvement of symptoms and signs. Results The overall efficacy of the experimental group was better than that of the control group, and the difference was statistically significant (P <0.05) in the time of fever relief, the change of signs and the length of hospital stay. Conclusion Pulmicort respules combined with ambroxol to treat neonatal pneumonia is effective in treating neonatal pneumonia. It can significantly improve the cure rate, improve the clinical symptoms and signs and shorten the course of the disease in children.